We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Lilly’s Olumiant with Remdesivir Reduces COVID-19 Recovery Time
Lilly’s Olumiant with Remdesivir Reduces COVID-19 Recovery Time
Eli Lilly says its rheumatoid arthritis (RA) therapy Olumiant (baricitinib) combined with Gilead Sciences’ antiviral remdesivir reduced COVID-19 patient recovery time by 12.5 percent, or from eight to seven days, over remdesivir alone.